Randomised Evaluation of SOdium dialysate Levels on Vascular Events: A cluster clinical study
Principal Investigators: Associate Professor Meg Jardine
In the RESOLVE study, haemodialysis units Australia, New Zealand, China, India and other interested countries will be randomised for all patients to receive one of two sodium dialysate levels (137mmol/L or 140mmol/L). Incidents of major cardiovascular events are monitored (i.e. hospitalisation myocardial infarction, hospitalised stroke, coronary artery or cerebrovascular revascularisation and all-cause death) with study data collected using existing registries (i.e. ANZDATA in Australia and New Zealand). Both New Zealand HRC and Australian NHMRC project funding have been applied for. International collaboration is led by the George Institute, Sydney and Australian collaboration is led by the Australasian Kidney Trials Network.